Downloads

Key performance indicators
(IFRS)

Key performance indicators (IFRS)

 

 

2024/25

 

2023/24

 

2022/23

 

 

€m

 

%

 

€m

 

%

 

€m

 

%

Revenue

 

2,227.6

 

100.0

 

2,066.1

 

100.0

 

2,089.3

 

100.0

Research and development expenses

 

326.3

 

14.6

 

343.1

 

16.6

 

349.3

 

16.7

EBITA1

 

257.7

 

11.6

 

248.9

 

12.0

 

358.6

 

17.2

Consolidated profit

 

142.3

 

6.3

 

180.2

 

8.7

 

292.0

 

14.0

Earnings per share (in €)

 

1.61

 

 

 

2.01

 

 

 

3.25

 

 

Dividend per share2 (in €)

 

0.55

 

 

 

0.60

 

 

 

1.10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flow from operating activities

 

209.9

 

 

 

247.3

 

 

 

250.9

 

 

Cash flow from investing activities

 

-91.0

 

 

 

-412.3

 

 

 

-111.0

 

 

Cash flow from financing activities

 

-108.8

 

 

 

176.2

 

 

 

-135.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

30 Sep 2025

 

30 Sep 2024

 

30 Sep 2023

 

 

€m

 

%

 

€m

 

%

 

€m

 

%

Total assets

 

3,403.4

 

100.0

 

3,393.2

 

100.0

 

3,032.9

 

100.0

Property, plant and equipment

 

343.0

 

10.1

 

353.8

 

10.4

 

315.8

 

10.4

Equity

 

2,127.7

 

62.5

 

2,056.5

 

60.6

 

2,172.9

 

71.6

Net financial debt3

 

-276.9

 

 

 

-327.4

 

 

 

863.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

30 Sep 2025

 

30 Sep 2024

 

30 Sep 2023

Return on equity

 

 

 

6.6%

 

 

 

8.7%

 

 

 

13.4%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

30 Sep 2025

 

30 Sep 2024

 

30 Sep 2023

 

 

Number

 

Number

 

Number

Employees

 

 

 

5,784

 

 

 

5,726

 

 

 

4,823

1

Earnings before interest, taxes and amortization on intangible assets from purchase price allocations

2

Amount proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG

3

Fiscal year 2022/23 shows the net liquidity (Cash and cash equivalents plus treasury receivables from/payables to the treasury of Carl Zeiss AG).

Share